Role of sodium-glucose cotransporter 2 inhibition to mitigate diabetic kidney disease risk in type 1 diabetes

por van Raalte, Daniël H, Bjornstad, Petter
Publicado 2020

Safety of Semaglutide

por Smits, Mark M., Van Raalte, Daniël H.
Publicado 2021

Corrigendum: Safety of Semaglutide

por Smits, Mark M., Van Raalte, Daniël H.
Publicado 2021

Editorial: Sodium Glucose Co-Transporter 2 Inhibitors and Kidney Function

por Van Raalte, Daniel H., Heerspink, Hiddo Lambers
Publicado 2022

Nephroprotective effects of GLP-1 receptor agonists: where do we stand?

por Mosterd, Charlotte M., Bjornstad, Petter, van Raalte, Daniël H.
Publicado 2020

Short‐Term Glucocorticoid Treatment Reduces Circulating Sclerostin Concentrations in Healthy Young Men: A Randomized, Placebo‐Controlled, Double‐Blind Study

por Jacobsson, Merel, van Raalte, Daniël H, Heijboer, Annemieke C, den Heijer, Martin, de Jongh, Renate T
Publicado 2020

Serum sclerostin is negatively associated with insulin sensitivity in obese but not lean women

por Aznou, Anouar, Meijer, Rick, van Raalte, Daniel, den Heijer, Martin, Heijboer, Annemieke, de Jongh, Renate
Publicado 2021

OR31-06 Gender-Affirming Hormone Therapy Affects Serum Cystatin C-based eGFR In Transgender Individuals

por van Eeghen, Sarah A, Wiepjes, Chantal, Nokoff, Natalie, Bjornstad, Petter, Heijer, Martin Den, van Raalte, Daniël
Publicado 2023

Glucagon-Like Peptide-1 Receptor Agonist Treatment Prevents Glucocorticoid-Induced Glucose Intolerance and Islet-Cell Dysfunction in Humans

por van Raalte, Daniël H., van Genugten, Renate E., Linssen, Margot M.L., Ouwens, D. Margriet, Diamant, Michaela
Publicado 2011

Causality of small and large intestinal microbiota in weight regulation and insulin resistance

por Scheithauer, Torsten P.M., Dallinga-Thie, Geesje M., de Vos, Willem M., Nieuwdorp, Max, van Raalte, Daniël H.
Publicado 2016

Incident Diabetes Risk Is Not Increased in Transgender Individuals Using Hormone Therapy

por van Velzen, Daan, Wiepjes, Chantal, Nota, Nienke, van Raalte, Daniel, de Mutsert, Renée, Simsek, Suat, den Heijer, Martin
Publicado 2021

Compensatory intestinal immunoglobulin response after vancomycin treatment in humans

por Scheithauer, Torsten P. M., Bakker, Guido J., Winkelmeijer, Maaike, Davids, Mark, Nieuwdorp, Max, van Raalte, Daniël H., Herrema, Hilde
Publicado 2021

Mechanisms underlying the blood pressure‐lowering effects of empagliflozin, losartan and their combination in people with type 2 diabetes: A secondary analysis of a randomized cros...

por Scholtes, Rosalie A., Mosterd, Charlotte M., Hesp, Anne C., Smits, Mark M., Heerspink, Hiddo J. L., van Raalte, Daniël H.
Publicado 2022

Gut Microbiota as a Trigger for Metabolic Inflammation in Obesity and Type 2 Diabetes

por Scheithauer, Torsten P. M., Rampanelli, Elena, Nieuwdorp, Max, Vallance, Bruce A., Verchere, C. Bruce, van Raalte, Daniël H., Herrema, Hilde
Publicado 2020

Plasma uric acid and renal haemodynamics in type 2 diabetes patients

por Suijk, Danii LS, Smits, Mark M, Muskiet, Marcel HA, Tonneijck, Lennart, Kramer, Mark HH, Joles, Jaap A, van Raalte, Daniël H
Publicado 2019

Effects of dipeptidyl peptidase‐4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis...

por Kraaijenhof, Jordan, Muskiet, Marcel H. A., Tonneijck, Lennart, Ouwens, D. Margriet, Kramer, Mark H. H., van Raalte, Daniël H., Smits, Mark M.
Publicado 2020

The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure

por BJORNSTAD, PETTER, GREASLEY, PETER J., WHEELER, DAVID C., CHERTOW, GLENN M., LANGKILDE, ANNA MARIA, HEERSPINK, HIDDO J.L., VAN RAALTE, DANIËL H.
Publicado 2021

The incretin pathway as a therapeutic target in diabetic kidney disease: a clinical focus on GLP-1 receptor agonists

por van Baar, Michaël J. B., van der Aart, Annemarie B., Hoogenberg, Klaas, Joles, Jaap A., Heerspink, Hiddo J. L., van Raalte, Daniël H.
Publicado 2019

Erratum. SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management. Diabetes Care 2018;41:1543–1556

por van Baar, Michaël J.B., van Ruiten, Charlotte C., Muskiet, Marcel H.A., van Bloemendaal, Liselotte, IJzerman, Richard G., van Raalte, Daniël H.
Publicado 2019

Glucosuria Interferes With Measurement of Effective Renal Plasma Flow Using para-Aminohippuric Acid, With a Focus on SGLT2 Inhibitors

por Scholtes, Rosalie A., Nguyen, Isabel T.N., van Bommel, Erik J.M., Willekes, Nel, van Nieuwenhuijzen, Melanie, van Raalte, Daniël H., Joles, Jaap A.
Publicado 2020